Skip to main content
보도자료 배포 뉴스와이어
검색폼
검색
로그인
회원가입
보도자료
서비스
교육
블로그
보도자료 배포
보도자료 구독
고객센터
보도자료 배포 서비스
보도자료 배포 뉴스와이어
보도자료 배포
보도자료 구독
고객센터
로그인
회원가입
보도자료
서비스
교육
블로그
통합검색
보도자료
사진
동영상
기업
박람회
FAQ
취소
기업 검색
보도자료 등록
최신
IT
건강
경제
교육
금융
농수산
라이프
레저
문화
미디어
부동산
사회
산업
스포츠
에너지
운송
유통
자동차
정책
신상품
상장기업
주요
최신 보도자료
MY뉴스
상장기업
사진
동영상
기업뉴스룸
박람회
인기 토픽
보도자료 분야와 RSS
English News
산업별
IT
건강
경제
교육
금융
농수산
라이프 스타일
레저
문화/연예
미디어
산업별
부동산
사회
산업
스포츠
에너지/환경
운송
유통
자동차
정책/정부
주제별
개발
공모/모집
기업문화
부고
분양
사업계획
사회공헌
선언/의견
설립/오픈
소송
수상/선정
수주
주제별
신상품
실적
인물동정
인사
인수/합병
전시/출품
정책
제휴
조사연구
채용
투자
판촉활동
지역별
서울
인천/경기
대전/충남
광주/전남
부산/울산/경남
대구/경북
강원
충북
전북
제주
해외
기업 뉴스룸
Boehringer Ingelheim International GmbH
이 회사 보도자료 구독
제약
INGELHEIM, Germany
http://www.boehringer-ingelheim.com
Boehringer Ingelheim International GmbH 보도자료
337개
RSS
이메일
2016년 2월 11일
14:25
The European Society of Cardiology announces winners of innovative cardiovascular research grant programme
The European Society of Cardiology (ESC) has announced five winners of the competitive research programme ‘Grants for Medical Research Innovation’, exclusively supported by an independent grant from Boehringer Ingelheim. The grants are awarded to res
건강
제약
수상/선정
2016년 2월 4일
18:35
SPIRIVA® RESPIMAT® Now Available in the U.S. for Maintenance Treatment of Asthma in Adults and Adolescents
Boehringer Ingelheim today announced that SPIRIVA® RESPIMAT® is now available for the treatment of asthma by prescription in U.S. pharmacies. The U.S. Food and Drug Administration (FDA) approved a once-daily dose of 2.5 µg for the long-term maintenan
건강
제약
신상품
2016년 1월 27일
17:25
Boehringer Ingelheim’s Giotrif® / Gilotrif® (afatinib) demonstrated superiority to Iressa® (gefitinib) in reducing the risk of disease progression and treatment failure in first-line treatment of...
Boehringer Ingelheim’s Giotrif® / Gilotrif® (afatinib) demonstrated superiority to Iressa® (gefitinib) in reducing the risk of disease progression and treatment failure in first-line treatment of patients with EGFR mutation-positive advanced non-smal
건강
제약
개발
2016년 1월 13일
17:55
Boehringer Ingelheim and Arena Pharmaceuticals Collaborate to Advance Research in Schizophrenia
Boehringer Ingelheim and Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced today that they have signed an exclusive agreement to conduct joint research to identify drug candidates targeting an undisclosed G protein-coupled receptor (GPCR), which b
건강
제약
제휴
2015년 12월 23일
10:55
Boehringer Ingelheim Invests in Europe: Pharma Company Expands Biopharmaceutical Production at Vienna Site
Boehringer Ingelheim will make a significant investment in biopharmaceutical production at its Vienna (Austria) site. There the research-driven pharmaceutical company will establish a new large-scale biopharmaceutical production facility for active i
건강
제약
투자
2015년 12월 21일
19:15
Boehringer Ingelheim 3rd-generation EGFR TKI, BI 1482694, receives FDA Breakthrough Therapy Designation in lung cancer
Boehringer Ingelheim today announced that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) for its novel, 3rd-generation, epidermal growth factor receptor (EGFR) mutation-specific tyrosine kinase inhibitor
건강
제약
개발
2015년 12월 21일
11:50
Boehringer Ingelheim presents strong lung cancer portfolio and long-awaited head-to-head data of afatinib compared to gefitinib at ESMO Asia 2015 Congress
Boehringer Ingelheim today announced that the latest data from its oncology portfolio will be presented at the ESMO Asia 2015 Congress in Singapore (http://goo.gl/7U6Olz), 18-21 December 2015. New data for BI 1482694 (https://goo.gl/Lu8ZyR)* (HM61713
건강
제약
개발
2015년 12월 15일
21:00
Sanofi and Boehringer Ingelheim Enter Exclusive Negotiations on Business Swap
Sanofi (http://en.sanofi.com)and Boehringer Ingelheim (www.boehringer-ingelheim.com) today announced that the companies have entered into exclusive negotiations to swap businesses. The proposed transaction would consist of an exchange of Sanofi anima
건강
제약
인수/합병
2015년 12월 15일
14:50
Initiation of first multinational study to evaluate safety of OFEV® (nintedanib) with add-on of pirfenidone in patients with IPF
Boehringer Ingelheim today announces the initiation of trial 1199.222 (ClinicalTrials.gov Identifier: NCT02579603), a new 12 week study to assess the safety, tolerability and pharmacokinetics of add-on treatment with pirfenidone to background therapy
건강
제약
개발
2015년 12월 9일
10:00
New Phase III study of nintedanib in people with systemic sclerosis and lung fibrosis
Boehringer Ingelheim announced today that the first person has been enrolled in the SENSCIS™ (Safety and Efficacy of Nintedanib in Systemic SClerosIS) study. The global Phase III trial, which is now open for recruitment, is investigating the efficacy
건강
제약
개발
2015년 12월 3일
10:15
Boehringer Ingelheim and MD Anderson Cancer Center join forces to discover new treatment approaches for pancreatic cancer
Boehringer Ingelheim and The University of Texas MD Anderson Cancer Center today announced a collaboration focused on developing innovative medicines for pancreatic ductal adenocarcinoma (PDAC). The new collaboration combines MD Anderson’s unique und
건강
제약
제휴
2015년 12월 1일
10:10
Lung cancer experts call for improved EGFR mutation testing to allow all eligible NSCLC patients access to personalised treatment
Insights from experts working on-the-ground in lung cancer, compiled by Boehringer Ingelheim, shed light on challenges faced by patients with advanced stage adenocarcinoma, a type of non-small cell lung cancer (NSCLC), in being tested for EGFR mutati
건강
제약
조사연구
2015년 11월 27일
11:15
Praxbind® (idarucizumab) approved in European Union for the specific reversal of Pradaxa® (dabigatran etexilate)
The European Commission has approved Praxbind® (idarucizumab), a treatment to rapidly and specifically reverse the anticoagulant effects of Pradaxa® (dabigatran etexilate) in cases of emergency surgery / urgent procedures or in situations of life-thr
건강
제약
개발
2015년 11월 17일
16:40
Time is of the Essence for Millions Living with ‘Neglected’ Lung Disease: Your Time Campaign Calls for Earlier Action in COPD
Boehringer Ingelheim today announced the launch of the Your Time campaign - a worldwide call to raise public awareness of chronic obstructive pulmonary disease (COPD) and the importance of acting now. By diagnosing and optimally managing the disease
건강
제약
행사
2015년 11월 16일
11:50
New Analyses Further Add to the Efficacy and Safety Profile of OFEV® (nintedanib) in Idiopathic Pulmonary Fibrosis (IPF)
Boehringer Ingelheim today announced the presentation of new analyses of OFEV® for the treatment of idiopathic pulmonary fibrosis (IPF) at the Pulmonary Fibrosis Foundation’s PFF Summit 2015 in Washington, D.C. In 2014, OFEV® became one of the first
건강
제약
개발
2015년 11월 12일
13:35
Boehringer Ingelheim Will Invest 11 Billion Euros in Research and Development in the Next Five Years to Accelerate the Discovery of Next Generation Medical Breakthroughs
Boehringer Ingelheim is launching a new research and development (R&D) strategy and a five-year R&D investment programme. This new plan was announced today at its R&D press conference in Berlin. The company pledges to invest a total of 11 billion eur
건강
제약
투자
2015년 11월 11일
10:55
Boehringer Ingelheim Announces Completed Enrollment of Phase III Clinical Trial for Biosimilar Candidate to Adalimumab
Boehringer Ingelheim today announced it has completed enrollment for the pivotal Phase III trial (NCT02137226, https://goo.gl/gUgvqd) of BI695501, a biosimilar candidate to adalimumab (AbbVie’s Humira®). This announcement was made following recent re
건강
제약
개발
2015년 11월 11일
10:40
Boehringer Ingelheim partners with leading scientific institutions in inflammatory bowel disease research
Boehringer Ingelheim today announced new collaborations with four major scientific partners to enrich research and development of novel therapeutic approaches for patients with inflammatory bowel disease (IBD), including the Icahn School of Medicine
건강
제약
제휴
2015년 11월 10일
18:25
Real-World Analysis of more than 44,000 Patients Reinforces Safety and Effectiveness of Pradaxa® in Routine Clinical Care
Brigham and Women’s Hospital in Boston, U.S., and Boehringer Ingelheim announce the results of a new interim analysis from a long-term study evaluating the safety and effectiveness of Pradaxa® (dabigatran etexilate) relative to warfarin in routine cl
건강
제약
개발
2015년 11월 10일
17:15
Boehringer Ingelheim Presents New idarucizumab (Praxbind®) Analyses on Reintroduction of Antithrombotic Therapy after Reversal of Dabigatran
Boehringer Ingelheim announces results from two new analyses evaluating idarucizumab, recently approved under the Accelerated Approval pathway and marketed in the U. S. as Praxbind®, a specific reversal agent for Pradaxa® (dabigatran etexilate), that
건강
제약
개발
2015년 11월 10일
14:00
New Jardiance® (empagliflozin) data show improved CV outcomes regardless of heart failure status at baseline
New sub-analysis data presented today show the reduction in risk for hospitalisation for heart failure or cardiovascular (CV) death with Jardiance®, compared with placebo when added to standard of care in patients with type 2 diabetes (T2D) at high r
건강
제약
개발
2015년 11월 9일
13:25
EMPA-REG OUTCOME®: Top-line renal data to be presented during American Society of Nephrology (ASN) Kidney Week 2015
Boehringer Ingelheim and Eli Lilly and Company today announced that top-line renal results from the EMPA-REG OUTCOME® study (compound empagliflozin, marketed under the name Jardiance®) will be presented during American Society of Nephrology (ASN) Kid
건강
제약
개발
2015년 11월 3일
17:25
Boehringer Ingelheim initiates pivotal programme for novel third-generation EGFR targeting lung cancer compound
Boehringer Ingelheim today announced at the BIO-Europe® conference in Munich, Germany, the initiation of a global Phase II trial evaluating the efficacy and safety of BI 1482694 (HM61713) in patients with T790M mutation-positive non-small cell lung c
건강
제약
개발
2015년 10월 29일
23:55
Boehringer Ingelheim’s Biosimilar Candidate Demonstrated Pharmacokinetic Bioequivalence to Adalimumab
Boehringer Ingelheim today announced results from a Phase I study (NCT02045979, https://goo.gl/ZaRHyV) of its biosimilar candidate (BI695501) for adalimumab (AbbVie’s Humira®), that demonstrated pharmacokinetic bioequivalence with both the U.S.-licen
건강
제약
개발
2015년 10월 29일
23:50
CHEST: New Sub-Analyses Show Improvement in COPD Patient Outcomes with Spiolto® Respimat®
Boehringer Ingelheim today announced the presentation of several new post-hoc analyses from the TONADO® 1&2 and OTEMTO® 1&2 studies at the American College of CHEST Physicians Annual Meeting in Montreal. One analysis showed significant lung function
건강
제약
개발
이전
7
8
9
10
11
다음
동영상
Final results from landmark DYNAGITO® trial published in The Lancet Respiratory Medicine
회사 보도자료 구독
뉴스와이어 회원은 이 회사 보도자료를 이메일과
MY뉴스
를 통해 무료로 구독할 수 있습니다.
회원 가입하기